Skip Navigation

San Antonio Breast Cancer Symposium (SABCS)

  • December 10 – 14, 2019
    Henry B. Gonzalez Conference Center, San Antonio, TX

    Dana-Farber at SABCS 2019

  • Jennifer Ligibel, MD, at SABCS in 2018

  • Dana-Farber breast oncologists, surgeons, and researchers are participating in the 2019 San Antonio Breast Cancer symposium. Our faculty are sharing results from clinical trials and recent research studies, and are leading a variety of conversations on improving breast cancer care.

    Follow along on Twitter: #SABCS19

    Schedule of Presentations by Dana-Farber Faculty

    As leaders in breast cancer research, physicians and scientists from Dana-Farber Cancer Institute are participating in workshops, general sessions, and forums at SABCS 2019.

    View the schedule of presentations by Dana-Farber faculty for Tuesday through Friday

    Dana-Farber Researchers Present Major Studies at SABCS

    Presentations include:

  • Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB Trial
    This trial looked at a new breast cancer drug called tucatinib, combined with standard therapies.


    • Results from the phase 2 DESTINY-01 study showing a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer. Details in video below:
  • Ian Krop, MD, PhD, Presents Results from the Phase 2 DESTINY-01 Study
    This study showed how a new antibody-drug conjugate helped prevent cancer progression in women with advanced HER2+ breast cancer.


    • Results from the Phase 2 ATEMPT trial exploring a less toxic therapy for early state HER2+ breast cancer. Details in video below:
  • Sara Tolaney, MD, MPH, Presents Results from the Phase 2 ATEMPT Trial
    The Phase 2 ATEMPT trial explored a less toxic therapy for early state HER2+ breast cancer.